ClinicalTrials.gg
CompletedNCT02467270OPTICUpdated Mar 17, 2026Results posted

Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of Doses

A Phase 2 interventional study of Ponatinib in Myeloid Leukemia, Chronic, Chronic Phase, sponsored by Takeda. Completed at 86 sites in 21 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-17.

Sponsored by Takeda · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
283
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 339 studies in Leukemia, Myeloid, Chronic-Phase with a site in United States — 12 open to participants now, 27 under way, 2 of them phase 3. Leukemia, Myeloid, Chronic-Phase · United States.

Enrollment
15th of 255
283 · median 38
Started
2015
with 4 others
Phase 2
139 of 339
3 open now
Registered
298th of 339
by date

Among the 339 studies in Leukemia, Myeloid, Chronic-Phase with a site in United States, this one is the 15th largest by enrollment of the 255 interventional ones that give a count, is one of 5 that started in 2015, is one of 139 in phase 2, and was the 298th registered.

Leukemia, Myeloid, Chronic-Phase

439 studies on the registry are indexed under Leukemia, Myeloid, Chronic-Phase; 27 are open to participants now.

Browse Leukemia, Myeloid, Chronic-Phase studies →

Open to participants now

12 of the 339 studies in Leukemia, Myeloid, Chronic-Phase with a site in United States are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 21 Leukemia, Myeloid, Chronic-Phase studies recruiting now, 14 (67%) set no upper age limit and 5 (24%) stop at 75 or younger; 3 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 339 studies in Leukemia, Myeloid, Chronic-Phase with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to characterize the efficacy of ponatinib administered in 3 starting doses (45 mg, 30 mg, and 15 mg daily) in participants with CP-CML who are resistant to prior tyrosine-kinase inhibitor (TKI) therapy or have T315I mutation, as measured by \<=1 % Breakpoint Cluster Region-Abelson Transcript Level using International Scale (BCR-ABL1IS) at 12 months.

Read the detailed description

The drug being tested in this study is ponatinib. This study will characterize the safety and efficacy of ponatinib over a range of 3 starting doses.

The study will enroll 276 participants in 3 cohorts and each cohort will have 92 participants. All the participants will be randomized to receive once-daily oral administration of 1 of 3 starting doses of ponatinib:

  • Cohort A: 45 mg ponatinib tablet
  • Cohort B: 30 mg ponatinib tablet
  • Cohort C: 15 mg ponatinib tablet

The study is designed to consist of 2 periods: 24-cycle Main treatment period and optional treatment continuation period. Participants will be treated with their randomized dose of study drug in the Main Treatment Period until the occurrence of at least one of the following: absence of CHR by 3 months, absence of MCyR at 12 months, absence of \<=1% BCR-ABL1IS at 12 months, loss of \<=1% BCR-ABL1IS development of intolerance, or completion of all 24 cycles of treatment (whichever occurs first). Following completion of approximately 5 years or following early withdrawal, participants may enter into an optional treatment continuation period.

This multi-center trial will be conducted in the United States, United Kingdom, Republic of Korea, Spain, France, Taiwan, Australia, Canada, Italy, Chile, Japan, Germany, Argentina, Poland, Czech Republic, Denmark, Hong Kong, Portugal, Russia, Singapore, Switzerland, and Sweden. The overall time to participate in this study is approximately 96 months. Participants will make a final visit to the clinic approximately 30 days after the last dose of study treatment.

03

Conditions studied

  • Myeloid Leukemia, Chronic, Chronic Phase

Keywords

  • Chronic Phase Chronic Myeloid Leukemia
  • Molecular Response
  • CML
  • Leukemia
  • Leukemia, Myeloid
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive
  • Neoplasms by Histologic Type
  • Neoplasms
  • Myeloproliferative Disorders
  • Bone Marrow Diseases
  • Hematologic Diseases
  • CP-CML
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Have chronic phase-chronic myelogenous leukemia/chronic myeloid leukemia (CP-CML) and have received at least two prior tyrosine kinase inhibitor (TKI) therapies and have demonstrated resistance to treatment OR have documented history of presence of T315I mutation after receiving any number of prior TKI.

    o] The diagnosis of chronic myeloid leukemia (CML) will be made using standard hematopathologic and cytogenetic criteria; CP-CML will be defined by all of the following: i \<15% blasts in bone marrow ii \<30% blasts plus promyelocytes in bone marrow iii \<20% basophils in peripheral blood. iv >= 100*10\^9/liter (L) (>=100,000/mm\^3). v No evidence of extramedullary disease except hepatosplenomegaly vi No prior diagnosis of AP-CML, and BP-CML o] Cytogenetic assessment at screening must demonstrate the BCR-ABL1 fusion by presence of the t(9;22) Philadelphia chromosome.

    i Variant translocations are only allowed provided they meet inclusion criterion 1d.

    o] Resistance to prior TKI therapy is defined as follows (participants must meet at least 1 criterion): i Three months after the initiation of prior TKI therapy: No cytogenetic response (>95% Ph+) or failure to achieve CHR or new mutation ii Six months after the initiation of prior TKI therapy: BCR-ABL1IS >10% and/or Ph+ >65% or new mutation iii Twelve months after the initiation of prior TKI therapy: BCR ABL1IS >10% and/or Ph+ >35% or new mutation iv At any time after the initiation of prior TKI therapy, the development of a new BCR-ABL1 kinase domain mutation(s) v At any time after the initiation of prior TKI therapy, the development of new clonal evolution vi At any time after the initiation of prior TKI therapy, the loss of CHR, or CCyR, or the confirmed loss of MMR in 2 consecutive tests, one of which has a BCR-ABL1IS transcript level of >=1% or new mutation o] >1% of BCR-ABL1IS as shown by real-time polymerase chain reaction

  2. Have an (ECOG) performance status of 0, 1, or 2.
  3. Have adequate renal function as defined by the following criterion:

    o] Serum creatinine \<=1.5* for institution o] Estimated >=30 milliliter per minute (mL/min) (Cockcroft-Gault formula)

  4. Have adequate hepatic function as defined by the following criteria:

    o] Total serum \<=1.5*ULN, unless due to Gilbert's syndrome o] (ALT) \<=2.5*ULN, or \<=5*ULN if leukemic infiltration of the liver is present o] Aspartate transaminase (AST) \<=2.5*ULN, or \<=5*ULN if leukemic infiltration of the liver is present

  5. Have normal pancreatic status as defined by the following criterion:

    o] Serum lipase and amylase \<=1.5*ULN

  6. Have normal corrected (Frederica) (QTcF) interval on screening (ECG) evaluation, defined as QTcF of \<=450 milliseconds (ms) in males or \<=470 ms in females.
  7. Have a negative pregnancy test documented prior to enrollment (for females of ).
  8. Agree to use a highly effective form of with sexual partners from randomization through at least 4 months after the end of treatment (for female and male participants who are fertile).
  9. Provide written .
  10. Be willing and able to comply with scheduled visits and study procedures.
  11. Have recovered from toxicities related to prior anticancer therapy to National Cancer Institute (NCI) (CTCAE) v 4.0 grade \<=1.

Exclusion criteria

Exclusion Criteria:

  1. Have used any approved TKIs or agents within 2 weeks or 6 half-lives of the agent, whichever is longer, prior to receiving study drug.
  2. Received interferon, cytarabine, or immunotherapy within 14 days, or any other cytotoxic chemotherapy, radiotherapy, or investigational therapy within 28 days prior to receiving the first dose of ponatinib, or have not recovered (>grade 1 by , version 4.0) from AEs (except alopecia), due to agents previously administered.
  3. Have undergone or allogeneic stem cell transplant \<60 days prior to receiving the first dose of ponatinib; have any evidence of ongoing (GVHD) or GVHD requiring therapy.
  4. Are being considered for hematopoietic stem cell transplant (HSCT) within 6-12 months of enrollment (note: ponatinib is not to be used as a bridge to HSCT in this trial).
  5. Are taking medications with a known risk of Torsades de Pointes.
  6. Have previously been treated with ponatinib.
  7. Have active CNS disease as evidenced by cytology or pathology; in the absence of clinical CNS disease, lumbar puncture is not required. History itself of CNS involvement is not exclusionary if CNS has been cleared with a documented negative lumbar puncture.
  8. Have , uncontrolled, or active cardiovascular disease, specifically including, but not restricted to:

    o] Any history of myocardial infarction (MI), unstable angina, cerebrovascular accident, or (TIA) o] Any history of peripheral vascular infarction, including visceral infarction o] Any revascularization procedure, including the placement of a stent o] Congestive heart failure (CHF) ( [NYHA] class III or IV) within 6 months prior to enrollment, or (LVEF) less than lower limit of normal, per local institutional standards, within 6 months prior to enrollment o] History of clinically significant (as determined by the treating physician) atrial arrhythmia or any history of ventricular arrhythmia o] Venous thromboembolism, including deep venous thrombosis or pulmonary embolism, within 6 months prior to enrollment

  9. Have uncontrolled hypertension (that is, >150 and >90 for systolic blood pressure (SBP) and diastolic blood pressure (DBP) respectively). Participants with hypertension should be under treatment at study entry to ensure blood pressure control. Those requiring 3 or more antihypertensive medications should be discussed with the medical monitor.
  10. Have poorly controlled diabetes defined as values of >7.5%. Participants with preexisting, well-controlled diabetes are not excluded.
  11. Have a significant bleeding disorder unrelated to CML.
  12. Have a history of alcohol abuse.
  13. Have a history of either acute pancreatitis within 1 year of study enrollment or of chronic pancreatitis.
  14. Have malabsorption syndrome or other gastrointestinal illness that could affect oral absorption of study drug.
  15. Have a history of another , other than cervical cancer in situ or basal cell or squamous cell carcinoma of the skin; the exception is if participants have been disease-free for at least 5 years, and are deemed by the investigator to be at low risk for recurrence of that malignancy.
  16. Are pregnant or lactating.
  17. Have undergone major surgery (with the exception of minor surgical procedures, such as catheter placement or BM ) within 14 days prior to first dose of ponatinib.
  18. Have an active infection which requires intravenous antibiotics.
  19. Have a known history of infection; testing is not required in the absence of prior documentation or known history.
  20. Have any condition or illness that, in the opinion of the investigator, would compromise participant safety or interfere with the evaluation of the drug.
  21. Have to the ponatinib active substance or to any of its inactive ingredients.
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
283 participants (actual)

Study arms

  • Experimental
    Treatment Period: Cohort A: Ponatinib 45 milligrams (mg)

    Participants received ponatinib 45 mg orally once daily in each 28-day cycle until achievement of ≤1% BCR-ABL1IS. Once ≤1% BCR-ABL1IS was achieved, participants received reduced dose of ponatinib 15 mg orally once daily.

    Drug: Ponatinib

  • Experimental
    Treatment Period: Cohort B: Ponatinib 30 mg

    Participants received ponatinib 30 mg orally once daily in each 28 day Cycle until achievement of ≤1% BCR-ABL1IS. Once ≤1% BCR-ABL1IS was achieved, participants received reduced dose of ponatinib 15 mg orally once daily.

    Drug: Ponatinib

  • Experimental
    Treatment Period: Cohort C: Ponatinib 15 mg

    Participants received ponatinib 15 mg orally once daily in each 28 day Cycle.

    Drug: Ponatinib

  • Experimental
    Close-out Period: Cohort A: Ponatinib 45 mg

    Participants received ponatinib 45 mg orally once daily in each 28-day cycle until achievement of ≤1% BCR-ABL1IS. Once ≤1% BCR-ABL1IS was achieved, participants received reduced dose of ponatinib 15 mg orally once daily.

    Drug: Ponatinib

  • Experimental
    Close-out Period: Cohort B: Ponatinib 30 mg

    Participants received ponatinib 30 mg orally once daily in each 28 day Cycle until achievement of ≤1% BCR-ABL1IS. Once ≤1% BCR-ABL1IS was achieved, participants received reduced dose of ponatinib 15 mg orally once daily.

    Drug: Ponatinib

  • Experimental
    Close-out Period: Cohort C: Ponatinib 15 mg

    Participants received ponatinib 15 mg orally once daily in each 28 day Cycle.

    Drug: Ponatinib

Interventions

  • Tablet, taken orally once daily.

    Also known as: Iclusig, AP24534

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Molecular Response (MR2: <=1% Breakpoint Cluster Region-Abelson Transcript Level) as Measured by the International Scale (BCR-ABL1IS) at Month 12

    MR2 was defined as a ratio of reverse transcribed transcript of BCR-ABL to ABL \<=1% Breakpoint Cluster Region-Abelson Transcript Level as measured by the International Scale (BCR-ABL1IS), equivalent to a 2-log reduction in transcript.

    Time frame: 12 months after the first dose of study treatment

Secondary outcomes

  1. Percentage of Participants With Major Molecular Response (MMR/MR3)

    MMR/MR3 was defined as a ratio of reverse transcribed transcript of BCR-ABL to ABL ≤0.1% on the international scale (equivalent to a 3-log reduction in transcript).

    Time frame: 12, 24 and 60 months after the first dose of study treatment

  2. Percentage of Participants With Major Cytogenetic Response (MCyR)

    MCyR was defined as percentage of participants with complete cytogenetic response (CCyR) or partial cytogenetic response (PCyR). Cytogenetic response is the percentage of Philadelphia chromosome positive (Ph+) metaphases in bone marrow (BM). Response is further defined as MCyR: CCyR or PCyR, where CCyR: 0% Ph + metaphases; PCyR: \>0 to 35% Ph + metaphases.

    Time frame: 12 months after the first dose of study treatment

  3. Duration of Major Molecular Response (MMR/MR3)

    Duration of MMR/MR3 was defined as the interval between the first assessment at which the criteria for \<=0.1% MMR were met until the earliest date at which loss of \<=0.1% MMR occurred, or the criteria for progression were met. Progression to accelerated phase (AP) was defined as: \>= 15% and \<30% blasts in peripheral blood or bone marrow or \>=20% basophils in peripheral blood or bone marrow or \>=30% blasts + promyelocytes in peripheral blood or bone marrow (but \<30% blasts) or \<100\*109 platelets per liter (/L) in peripheral blood unrelated to therapy or cytogenetic, genetic evidence of clonal evolution, and no extramedullary disease. Progression to blast phase (BP) was defined as: \>=30% blasts in peripheral blood or bone marrow or extramedullary disease other than hepatosplenomegaly.

    Time frame: Baseline up to approximately 8.9 years

  4. Percentage of Participants With Adjusted Incidence Rates for Treatment Emergent Arterial Occlusive Events (AOEs), Venous Thrombotic Events (VTEs), Adverse Events (AEs), and Serious AEs (SAEs)

    Percentage of participants with adjusted incidence rates who developed AOEs and VTEs were categorized according to arterial occlusive events and venous thrombotic events. AE is any untoward medical occurrence in participant administered medicinal investigational drug. Untoward medical occurrence does not necessarily have to have causal relationship with treatment. SAE is any untoward medical occurrence that results in death; is life-threatening; requires inpatient hospitalization or prolongation of present hospitalization; results in persistent or significant disability/incapacity; is congenital anomaly/birth defect/is medically important event that may not be immediately life-threatening/result in death or hospitalization, but may jeopardize participant/may require intervention to prevent one of other outcomes listed in definition above, or involves suspected transmission via a medicinal product of an infectious agent.

    Time frame: From first dose up to 30 days after last dose of the study drug (up to approximately 9.8 years)

  5. Percentage of Participants With Complete Cytogenetic Response (CCyR)

    Cytogenetic response was defined as the percentage of Ph+ metaphases in bone marrow (peripheral blood may not be used), with a review of a minimum of 20 metaphases. CCyR was defined as 0% Ph+ metaphases.

    Time frame: Month 12

  6. Percentage of Participants With Molecular Response 4 (MR4) and Molecular Response 4.5 (MR4.5)

    MR4 was defined as \<=0.01% BCR-ABL1IS. MR 4.5was defined as \<=0.0032% BCR-ALB1IS. MR4 and MR4.5 by each time point means the best outcome up to each time point after randomization.

    Time frame: Up to approximately 9.5 years

  7. Percentage of Participants With Molecular Response 1 (MR1)

    MR1 was defined as percentage of participants achieving a ratio of \<=10% Breakpoint Cluster Region-Abelson (BCR-ABL1) transcripts on the international scale. MR1 is molecular response with 1-log reduction in transcript.

    Time frame: 3 months after the first dose of study treatment

  8. Percentage of Participants With Complete Hematologic Response (CHR)

    CHR was defined as achieving all of the following measurements: white blood cells (WBC) \<= institutional upper limit of normal (ULN), platelets less than (\<)450,000 per cubic millimeter (/mm\^3), no blasts or promyelocytes in peripheral blood, \<5% myelocytes plus metamyelocytes in peripheral blood, basophils in peripheral blood \<5%, and no extramedullary involvement (including no hepatomegaly or splenomegaly).

    Time frame: 3 months after the first dose of study treatment

  9. Percentage of Participants With Treatment Emergent AEs Leading to Treatment Discontinuation, Dose Reduction and Dose Interruption

    An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A TEAE is defined as an adverse event with an onset that occurs after receiving study drug.

    Time frame: Up to approximately 9.8 years

  10. Kaplan-Meier Estimate of Duration of Response (DOR) of <=1% BCR-ABL1 IS (MR2) at Months 12 and 24

    DOR (≤1% BCR-ABL1IS) is defined as interval between first assessment at which criteria for ≤1% BCR-ABL1IS are met until earliest date at which loss of ≤1% BCR-ABL1IS occurs, or criteria for progression accelerated phase (AP) or blast Phase (BP) of chronic myeloid leukemia (CML) are met. Loss of ≤1% BCR-ABL1IS is an increase to \>1% of BCR-ABL1IS. Progression to AP: ≥15% and \<30% blasts in peripheral blood or bone marrow or ≥20% basophils in peripheral blood or bone marrow or ≥30% blasts + promyelocytes in peripheral blood or bone marrow (but \<30% blasts) or \<100\*109 platelets per liter in peripheral blood unrelated to therapy or cytogenetic, genetic evidence of clonal evolution, and no extramedullary disease. Progression to BP: ≥30% blasts in peripheral blood or bone marrow or extramedullary disease other than hepatosplenomegaly. Kaplan-Meier method was used for analysis of percentage of participants who achieved DOR of 12 and 24 months.

    Time frame: 12 and 24 months after the first dose of study treatment

  11. Kaplan-Meier Estimate of Duration of Response (DOR) of Major Molecular Response (MMR/MR3)

    Duration of MMR/MR3 is defined as interval between first assessment at which criteria for MMR are met until earliest date at which loss of MMR occurs, or criteria for progression (progression to AP or BP of CML) are met. Participants remaining in MMR will be censored at last date at which criteria for MMR are met. Loss of MMR is an increase to \>0.1% of BCR-ABL1IS. Progression to AP: \>= 15% and \<30% blasts in peripheral blood or bone marrow or \>=20% basophils in peripheral blood or bone marrow or \>=30% blasts+promyelocytes in peripheral blood or bone marrow (but \<30% blasts) or \<100\*109 platelets/L in peripheral blood unrelated to therapy or cytogenetic, genetic evidence of clonal evolution, and no extramedullary disease. Progression to BP: \>=30% blasts in peripheral blood or bone marrow or extramedullary disease other than hepatosplenomegaly. Kaplan-Meier method was used for analysis of percentage of participants who achieved DOR of 12 and 24 months.

    Time frame: 12 and 24 months after the first dose of study treatment

  12. Duration of Response in MR2 Responders

    Duration of response in "responders" was defined as any participants who achieved ≤1% BCR-ABL1IS (MR2) at any time during the study. Responders were defined as those participants who met all of the following: were randomized and treated, responded at 12 months after the initiation of study treatment, and underwent baseline polymerase chain reaction (PCR) assessment.

    Time frame: Baseline up to approximately 8.9 years

  13. Time to Response (MR2)

    Time to response was defined as the time interval from the date of the first dose of the study drug until the initial observation of CR or PR for participants with confirmed CR/PR. Response was defined as any participants who achieved ≤1% BCR-ABL1IS (MR2) at any time during the study. CR for target lesion: disappearance of all extranodal lesions and all pathological lymph nodes must have decreased to \<10 mm in short axis. CR for non-target lesion: Disappearance of all extranodal non-target lesions, all lymph nodes must be non-pathological in size (\<10mm short axis) and normalization of tumor marker level. PR: at least a 30% decrease in the SLD of target lesions, taking as reference the Baseline sum diameters.

    Time frame: Baseline up to approximately 5 years

  14. Percentage of Participants With Progression to Accelerated Phase (AP)-Chronic Myeloid Leukemia (CML) or Blast Phase (BP)-CML

    Progression to AP is defined as: \>=15% and \<30% blasts in peripheral blood or bone marrow or \>=20% basophils in peripheral blood or bone marrow or \>=30% blasts + promyelocytes in peripheral blood or bone marrow (but \<30% blasts) or \<100\*109 platelets/L in peripheral blood unrelated to therapy or cytogenetic, genetic evidence of clonal evolution, and no extramedullary disease. Progression to BP is defined as: \>=30% blasts in peripheral blood or bone marrow or extramedullary disease other than hepatosplenomegaly.

    Time frame: From first dose date of study treatment up to approximately 8.9 years

  15. Progression-free Survival (PFS)

    PFS was defined as the interval between the first dose date of study treatment and the first date at which the criteria for progression were met (progression to the AP or BP of CML), or death due to any cause, censored at the last response assessment. Progression to AP was defined as: \>=15% and \<30% blasts in peripheral blood or bone marrow or \>=20% basophils in peripheral blood or bone marrow or \>=30% blasts + promyelocytes in peripheral blood or bone marrow (but \<30% blasts) or \<100\*109 platelets/L in peripheral blood unrelated to therapy or cytogenetic, genetic evidence of clonal evolution, and no extramedullary disease. Progression to BP was defined as: \>=30% blasts in peripheral blood or bone marrow or extramedullary disease other than hepatosplenomegaly.

    Time frame: Up to approximately 8.9 years

  16. Overall Survival (OS)

    OS was defined as the interval between the first dose of study treatment and death due to any cause, censored at the last contact date when the participant was alive.

    Time frame: Up to approximately 8.9 years

07

Results

Posted Jun 14, 2021

Participant flow

Participants took part in the study at 61 investigative sites globally from 13 July 2015 to 23 April 2025.

Treatment Period (60 Months)
Participant flow — Treatment Period (60 Months)
MilestoneTreatment Period: Cohort A: Ponatinib 45 mgTreatment Period: Cohort B: Ponatinib 30 mgTreatment Period: Cohort C: Ponatinib 15 mgClose-out Period: Cohort A: Ponatinib 45 mgClose-out Period: Cohort B: Ponatinib 30 mgClose-out Period: Cohort C: Ponatinib 15 mg
Started949594000
Treated (safety population)949494000
Completed000000
Not completed949594000
Withdrew: Participants never treated010000
Withdrew: Ongoing at the end of treatment period271717000
Withdrew: Adverse event201917000
Withdrew: Progressive disease9107000
Withdrew: Death423000
Withdrew: Lack of efficacy162228000
Withdrew: Non-compliance with study drug021000
Withdrew: Lost to follow-up311000
Withdrew: Pregnancy110000
Withdrew: Transitioned to post-trial ponatinib access505000
Withdrew: Physician decision298000
Withdrew: Withdrawal by subject697000
Withdrew: Reason not specified120000
Close-out Period (11 Months)
Participant flow — Close-out Period (11 Months)
MilestoneTreatment Period: Cohort A: Ponatinib 45 mgTreatment Period: Cohort B: Ponatinib 30 mgTreatment Period: Cohort C: Ponatinib 15 mgClose-out Period: Cohort A: Ponatinib 45 mgClose-out Period: Cohort B: Ponatinib 30 mgClose-out Period: Cohort C: Ponatinib 15 mg
Started000271717
Completed000000
Not completed000271717
Withdrew: Transitioned to post-trial ponatinib access000241517
Withdrew: Adverse event000200
Withdrew: Progressive disease000100
Withdrew: Physician decision000010
Withdrew: Withdrawal by subject000010

Outcome measures

PrimaryPercentage of Participants With Molecular Response (MR2: <=1% Breakpoint Cluster Region-Abelson Transcript Level) as Measured by the International Scale (BCR-ABL1IS) at Month 12

MR2 was defined as a ratio of reverse transcribed transcript of BCR-ABL to ABL \<=1% Breakpoint Cluster Region-Abelson Transcript Level as measured by the International Scale (BCR-ABL1IS), equivalent to a 2-log reduction in transcript.

Time frame:
12 months after the first dose of study treatment
Reported as:
Number · percentage of participants
Percentage of Participants With Molecular Response (MR2: <=1% Breakpoint Cluster Region-Abelson Transcript Level) as Measured by the International Scale (BCR-ABL1IS) at Month 12
percentage of participantsTreatment Period: Cohort A: Ponatinib 45 mgTreatment Period: Cohort B: Ponatinib 30 mgTreatment Period: Cohort C: Ponatinib 15 mg
Percentage of Participants With Molecular Response (MR2: <=1% Breakpoint Cluster Region-Abelson Transcript Level) as Measured by the International Scale (BCR-ABL1IS) at Month 1244.1 (31.7 to 57.0)29.0 (18.4 to 41.6)23.1 (13.4 to 35.3)
SecondaryPercentage of Participants With Major Molecular Response (MMR/MR3)

MMR/MR3 was defined as a ratio of reverse transcribed transcript of BCR-ABL to ABL ≤0.1% on the international scale (equivalent to a 3-log reduction in transcript).

Time frame:
12, 24 and 60 months after the first dose of study treatment
Reported as:
Number · percentage of participants
Percentage of Participants With Major Molecular Response (MMR/MR3)
percentage of participantsTreatment Period: Cohort A: Ponatinib 45 mgTreatment Period: Cohort B: Ponatinib 30 mgTreatment Period: Cohort C: Ponatinib 15 mg
12 Months17.220.416.5
24 Months24.715.119.8
60 Months46.229.024.2
SecondaryPercentage of Participants With Major Cytogenetic Response (MCyR)

MCyR was defined as percentage of participants with complete cytogenetic response (CCyR) or partial cytogenetic response (PCyR). Cytogenetic response is the percentage of Philadelphia chromosome positive (Ph+) metaphases in bone marrow (BM). Response is further defined as MCyR: CCyR or PCyR, where CCyR: 0% Ph + metaphases; PCyR: \>0 to 35% Ph + metaphases.

Time frame:
12 months after the first dose of study treatment
Reported as:
Number · percentage of participants
Percentage of Participants With Major Cytogenetic Response (MCyR)
percentage of participantsTreatment Period: Cohort A: Ponatinib 45 mgTreatment Period: Cohort B: Ponatinib 30 mgTreatment Period: Cohort C: Ponatinib 15 mg
Percentage of Participants With Major Cytogenetic Response (MCyR)48.4 (37.7 to 59.1)30.0 (20.8 to 40.6)43.8 (33.3 to 54.7)
SecondaryDuration of Major Molecular Response (MMR/MR3)

Duration of MMR/MR3 was defined as the interval between the first assessment at which the criteria for \<=0.1% MMR were met until the earliest date at which loss of \<=0.1% MMR occurred, or the criteria for progression were met. Progression to accelerated phase (AP) was defined as: \>= 15% and \<30% blasts in peripheral blood or bone marrow or \>=20% basophils in peripheral blood or bone marrow or \>=30% blasts + promyelocytes in peripheral blood or bone marrow (but \<30% blasts) or \<100\*109 platelets per liter (/L) in peripheral blood unrelated to therapy or cytogenetic, genetic evidence of clonal evolution, and no extramedullary disease. Progression to blast phase (BP) was defined as: \>=30% blasts in peripheral blood or bone marrow or extramedullary disease other than hepatosplenomegaly.

Time frame:
Baseline up to approximately 8.9 years
Reported as:
Median · months
Duration of Major Molecular Response (MMR/MR3)
monthsTreatment Period: Cohort A: Ponatinib 45 mgTreatment Period: Cohort B: Ponatinib 30 mgTreatment Period: Cohort C: Ponatinib 15 mg
Duration of Major Molecular Response (MMR/MR3)NA (NA to NA)NA (27.3 to NA)NA (NA to NA)
SecondaryPercentage of Participants With Adjusted Incidence Rates for Treatment Emergent Arterial Occlusive Events (AOEs), Venous Thrombotic Events (VTEs), Adverse Events (AEs), and Serious AEs (SAEs)

Percentage of participants with adjusted incidence rates who developed AOEs and VTEs were categorized according to arterial occlusive events and venous thrombotic events. AE is any untoward medical occurrence in participant administered medicinal investigational drug. Untoward medical occurrence does not necessarily have to have causal relationship with treatment. SAE is any untoward medical occurrence that results in death; is life-threatening; requires inpatient hospitalization or prolongation of present hospitalization; results in persistent or significant disability/incapacity; is congenital anomaly/birth defect/is medically important event that may not be immediately life-threatening/result in death or hospitalization, but may jeopardize participant/may require intervention to prevent one of other outcomes listed in definition above, or involves suspected transmission via a medicinal product of an infectious agent.

Time frame:
From first dose up to 30 days after last dose of the study drug (up to approximately 9.8 years)
Reported as:
Number · percentage of participants
Percentage of Participants With Adjusted Incidence Rates for Treatment Emergent Arterial Occlusive Events (AOEs), Venous Thrombotic Events (VTEs), Adverse Events (AEs), and Serious AEs (SAEs)
percentage of participantsTreatment Period: Cohort A: Ponatinib 45 mgTreatment Period: Cohort B: Ponatinib 30 mgTreatment Period: Cohort C: Ponatinib 15 mgClose-out Period: Cohort A: Ponatinib 45 mgClose-out Period: Cohort B: Ponatinib 30 mgClose-out Period: Cohort C: Ponatinib 15 mg
AOEs13.89.65.33.711.80
VTEs1.11.11.1000
AEs100.097.997.974.194.176.5
SAEs40.435.141.53.717.60
SecondaryPercentage of Participants With Complete Cytogenetic Response (CCyR)

Cytogenetic response was defined as the percentage of Ph+ metaphases in bone marrow (peripheral blood may not be used), with a review of a minimum of 20 metaphases. CCyR was defined as 0% Ph+ metaphases.

Time frame:
Month 12
Reported as:
Number · percentage of participants
Percentage of Participants With Complete Cytogenetic Response (CCyR)
percentage of participantsTreatment Period: Cohort A: Ponatinib 45 mgTreatment Period: Cohort B: Ponatinib 30 mgTreatment Period: Cohort C: Ponatinib 15 mg
Percentage of Participants With Complete Cytogenetic Response (CCyR)34.118.929.2
SecondaryPercentage of Participants With Molecular Response 4 (MR4) and Molecular Response 4.5 (MR4.5)

MR4 was defined as \<=0.01% BCR-ABL1IS. MR 4.5was defined as \<=0.0032% BCR-ALB1IS. MR4 and MR4.5 by each time point means the best outcome up to each time point after randomization.

Time frame:
Up to approximately 9.5 years
Reported as:
Number · percentage of participants
Percentage of Participants With Molecular Response 4 (MR4) and Molecular Response 4.5 (MR4.5)
percentage of participantsTreatment Period: Cohort A: Ponatinib 45 mgTreatment Period: Cohort B: Ponatinib 30 mgTreatment Period: Cohort C: Ponatinib 15 mg
MR4: 3 Months1.1 (0.0 to 5.8)1.1 (0.0 to 5.8)0 (0.0 to 4.0)
MR4: 6 Months3.2 (0.7 to 9.1)2.2 (0.3 to 7.6)3.3 (0.7 to 9.3)
MR4: 9 Months5.4 (1.8 to 12.1)8.6 (3.8 to 16.2)5.5 (1.8 to 12.4)
MR4: 12 Months6.5 (2.4 to 13.5)9.7 (4.5 to 17.6)7.7 (3.1 to 15.2)
MR4: 15 Months6.5 (2.4 to 13.5)9.7 (4.5 to 17.6)8.8 (3.9 to 16.6)
MR4: 18 Months7.5 (3.1 to 14.9)9.7 (4.5 to 17.6)12.1 (6.2 to 20.6)
MR4: 21 Months7.5 (3.1 to 14.9)11.8 (6.1 to 20.2)12.1 (6.2 to 20.6)
MR4: 24 Months10.8 (5.3 to 18.9)12.9 (6.8 to 21.5)12.1 (6.2 to 20.6)
MR4: 27 Months11.8 (6.1 to 20.2)15.1 (8.5 to 24.0)13.2 (7.0 to 21.9)
MR4: 30 Months12.9 (6.8 to 21.5)15.1 (8.5 to 24.0)13.2 (7.0 to 21.9)
MR4: 33 Months16.1 (9.3 to 25.2)15.1 (8.5 to 24.0)13.2 (7.0 to 21.9)
MR4: 36 Months18.3 (11.0 to 27.6)15.1 (8.5 to 24.0)14.3 (7.8 to 23.2)
MR4: 39 Months19.4 (11.9 to 28.9)15.1 (8.5 to 24.0)17.6 (10.4 to 27.0)
MR4: 42 Months19.4 (11.9 to 28.9)15.1 (8.5 to 24.0)17.6 (10.4 to 27.0)
MR4: 45 Months19.4 (11.9 to 28.9)16.1 (9.3 to 25.2)18.7 (11.3 to 28.2)
MR4: 48 Months20.4 (12.8 to 30.1)16.1 (9.3 to 25.2)18.7 (11.3 to 28.2)
MR4: 51 Months21.5 (13.7 to 31.2)17.2 (10.2 to 26.4)18.7 (11.3 to 28.2)
MR4: 54 Months21.5 (13.7 to 31.2)17.2 (10.2 to 26.4)18.7 (11.3 to 28.2)
MR4: 57 Months21.5 (13.7 to 31.2)18.3 (11.0 to 27.6)18.7 (11.3 to 28.2)
MR4: 60 Months23.7 (15.5 to 33.6)18.3 (11.0 to 27.6)18.7 (11.3 to 28.2)
MR4: 63 Months23.7 (15.5 to 33.6)18.3 (11.0 to 27.6)18.7 (11.3 to 28.2)
MR4: 66 Months24.7 (16.4 to 34.8)19.4 (11.9 to 28.9)18.7 (11.3 to 28.2)
MR4: 69 Months24.7 (16.4 to 34.8)19.4 (11.9 to 28.9)18.7 (11.3 to 28.2)
MR4: 72 Months24.7 (16.4 to 34.8)19.4 (11.9 to 28.9)18.7 (11.3 to 28.2)
MR4: 75 Months24.7 (16.4 to 34.8)19.4 (11.9 to 28.9)19.8 (12.2 to 29.4)
MR4: 78 Months25.8 (17.3 to 35.9)19.4 (11.9 to 28.9)19.8 (12.2 to 29.4)
MR4: 81 Months25.8 (17.3 to 35.9)19.4 (11.9 to 28.9)19.8 (12.2 to 29.4)
MR4: 84 Months25.8 (17.3 to 35.9)19.4 (11.9 to 28.9)19.8 (12.2 to 29.4)
MR4: 87 Months25.8 (17.3 to 35.9)19.4 (11.9 to 28.9)19.8 (12.2 to 29.4)
MR4: 90 Months25.8 (17.3 to 35.9)19.4 (11.9 to 28.9)19.8 (12.2 to 29.4)
MR4: 93 Months25.8 (17.3 to 35.9)19.4 (11.9 to 28.9)19.8 (12.2 to 29.4)
MR4: 96 Months25.8 (17.3 to 35.9)19.4 (11.9 to 28.9)19.8 (12.2 to 29.4)
MR4: 99 Months25.8 (17.3 to 35.9)19.4 (11.9 to 28.9)19.8 (12.2 to 29.4)
MR4: 102 Months25.8 (17.3 to 35.9)19.4 (11.9 to 28.9)19.8 (12.2 to 29.4)
MR4: 105 Months25.8 (17.3 to 35.9)19.4 (11.9 to 28.9)19.8 (12.2 to 29.4)
MR4: 108 Months25.8 (17.3 to 35.9)19.4 (11.9 to 28.9)19.8 (12.2 to 29.4)
MR4: 111 Months25.8 (17.3 to 35.9)19.4 (11.9 to 28.9)19.8 (12.2 to 29.4)
MR4: 114 Months25.8 (17.3 to 35.9)19.4 (11.9 to 28.9)19.8 (12.2 to 29.4)
MR4.5: 3 Months1.1 (0.0 to 5.8)0 (0.0 to 3.9)0 (0.0 to 4.0)
MR4.5: 6 Months1.1 (0.0 to 5.8)1.1 (0.0 to 5.8)0 (0.0 to 4.0)
MR4.5: 9 Months2.2 (0.3 to 7.6)3.2 (0.7 to 9.1)2.2 (0.3 to 7.7)
MR4.5: 12 Months4.3 (1.2 to 10.6)6.5 (2.4 to 13.5)2.2 (0.3 to 7.7)
MR4.5: 15 Months4.3 (1.2 to 10.6)7.5 (3.1 to 14.9)3.3 (0.7 to 9.3)
MR4.5: 18 Months5.4 (1.8 to 12.1)7.5 (3.1 to 14.9)4.4 (1.2 to 10.9)
MR4.5: 21 Months5.4 (1.8 to 12.1)7.5 (3.1 to 14.9)6.6 (2.5 to 13.8)
MR4.5: 24 Months5.4 (1.8 to 12.1)8.6 (3.8 to 16.2)8.8 (3.9 to 16.6)
MR4.5: 27 Months5.4 (1.8 to 12.1)8.6 (3.8 to 16.2)8.8 (3.9 to 16.6)
MR4.5: 30 Months6.5 (2.4 to 13.5)8.6 (3.8 to 16.2)9.9 (4.6 to 17.9)
MR4.5: 33 Months6.5 (2.4 to 13.5)8.6 (3.8 to 16.2)9.9 (4.6 to 17.9)
MR4.5: 36 Months11.8 (6.1 to 20.2)9.7 (4.5 to 17.6)11.0 (5.4 to 19.3)
MR4.5: 39 Months11.8 (6.1 to 20.2)9.7 (4.5 to 17.6)12.1 (6.2 to 20.6)
MR4.5: 42 Months11.8 (6.1 to 20.2)10.8 (5.3 to 18.9)13.2 (7.0 to 21.9)
MR4.5: 45 Months11.8 (6.1 to 20.2)10.8 (5.3 to 18.9)15.4 (8.7 to 24.5)
MR4.5: 48 Months11.8 (6.1 to 20.2)10.8 (5.3 to 18.9)15.4 (8.7 to 24.5)
MR4.5: 51 Months11.8 (6.1 to 20.2)12.9 (6.8 to 21.5)15.4 (8.7 to 24.5)
MR4.5: 54 Months12.9 (6.8 to 21.5)12.9 (6.8 to 21.5)15.4 (8.7 to 24.5)
MR4.5: 57 Months12.9 (6.8 to 21.5)14.0 (7.7 to 22.7)15.4 (8.7 to 24.5)
MR4.5: 60 Months12.9 (6.8 to 21.5)14.0 (7.7 to 22.7)15.4 (8.7 to 24.5)
MR4.5: 63 Months12.9 (6.8 to 21.5)15.1 (8.5 to 24.0)15.4 (8.7 to 24.5)
MR4.5: 66 Months12.9 (6.8 to 21.5)15.1 (8.5 to 24.0)15.4 (8.7 to 24.5)
MR4.5: 69 Months12.9 (6.8 to 21.5)15.1 (8.5 to 24.0)16.5 (9.5 to 25.7)
MR4.5: 72 Months14.0 (7.7 to 22.7)15.1 (8.5 to 24.0)17.6 (10.4 to 27.0)
MR4.5: 75 Months14.0 (7.7 to 22.7)15.1 (8.5 to 24.0)17.6 (10.4 to 27.0)
MR4.5: 78 Months14.0 (7.7 to 22.7)15.1 (8.5 to 24.0)17.6 (10.4 to 27.0)
MR4.5: 81 Months14.0 (7.7 to 22.7)15.1 (8.5 to 24.0)17.6 (10.4 to 27.0)
MR4.5: 84 Months15.1 (8.5 to 24.0)15.1 (8.5 to 24.0)17.6 (10.4 to 27.0)
MR4.5: 87 Months15.1 (8.5 to 24.0)15.1 (8.5 to 24.0)17.6 (10.4 to 27.0)
MR4.5: 90 Months15.1 (8.5 to 24.0)15.1 (8.5 to 24.0)17.6 (10.4 to 27.0)
MR4.5: 93 Months15.1 (8.5 to 24.0)15.1 (8.5 to 24.0)17.6 (10.4 to 27.0)
MR4.5: 96 Months15.1 (8.5 to 24.0)15.1 (8.5 to 24.0)17.6 (10.4 to 27.0)
MR4.5: 99 Months15.1 (8.5 to 24.0)15.1 (8.5 to 24.0)17.6 (10.4 to 27.0)
MR4.5: 102 Months15.1 (8.5 to 24.0)15.1 (8.5 to 24.0)17.6 (10.4 to 27.0)
MR4.5: 105 Months15.1 (8.5 to 24.0)15.1 (8.5 to 24.0)17.6 (10.4 to 27.0)
MR4.5: 108 Months15.1 (8.5 to 24.0)15.1 (8.5 to 24.0)17.6 (10.4 to 27.0)
MR4.5: 111 Months15.1 (8.5 to 24.0)15.1 (8.5 to 24.0)17.6 (10.4 to 27.0)
MR4.5: 114 Months15.1 (8.5 to 24.0)15.1 (8.5 to 24.0)17.6 (10.4 to 27.0)
SecondaryPercentage of Participants With Molecular Response 1 (MR1)

MR1 was defined as percentage of participants achieving a ratio of \<=10% Breakpoint Cluster Region-Abelson (BCR-ABL1) transcripts on the international scale. MR1 is molecular response with 1-log reduction in transcript.

Time frame:
3 months after the first dose of study treatment
Reported as:
Number · percentage of participants
Percentage of Participants With Molecular Response 1 (MR1)
percentage of participantsTreatment Period: Cohort A: Ponatinib 45 mgTreatment Period: Cohort B: Ponatinib 30 mgTreatment Period: Cohort C: Ponatinib 15 mg
Percentage of Participants With Molecular Response 1 (MR1)52.744.142.9
SecondaryPercentage of Participants With Complete Hematologic Response (CHR)

CHR was defined as achieving all of the following measurements: white blood cells (WBC) \<= institutional upper limit of normal (ULN), platelets less than (\<)450,000 per cubic millimeter (/mm\^3), no blasts or promyelocytes in peripheral blood, \<5% myelocytes plus metamyelocytes in peripheral blood, basophils in peripheral blood \<5%, and no extramedullary involvement (including no hepatomegaly or splenomegaly).

Time frame:
3 months after the first dose of study treatment
Reported as:
Number · percentage of participants
Percentage of Participants With Complete Hematologic Response (CHR)
percentage of participantsTreatment Period: Cohort A: Ponatinib 45 mgTreatment Period: Cohort B: Ponatinib 30 mgTreatment Period: Cohort C: Ponatinib 15 mg
Percentage of Participants With Complete Hematologic Response (CHR)87.2 (78.8 to 93.2)81.1 (71.7 to 88.4)81.9 (72.6 to 89.1)
SecondaryPercentage of Participants With Treatment Emergent AEs Leading to Treatment Discontinuation, Dose Reduction and Dose Interruption

An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A TEAE is defined as an adverse event with an onset that occurs after receiving study drug.

Time frame:
Up to approximately 9.8 years
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment Emergent AEs Leading to Treatment Discontinuation, Dose Reduction and Dose Interruption
percentage of participantsTreatment Period: Cohort A: Ponatinib 45 mgTreatment Period: Cohort B: Ponatinib 30 mgTreatment Period: Cohort C: Ponatinib 15 mgClose-out Period: Cohort A: Ponatinib 45 mgClose-out Period: Cohort B: Ponatinib 30 mgClose-out Period: Cohort C: Ponatinib 15 mg
TEAEs Leading to Treatment Discontinuation24.519.120.23.700
TEAEs Leading to Dose Reduction51.139.434.03.700
TEAEs Leading to Dose Interruption80.968.166.07.411.85.9
SecondaryKaplan-Meier Estimate of Duration of Response (DOR) of <=1% BCR-ABL1 IS (MR2) at Months 12 and 24

DOR (≤1% BCR-ABL1IS) is defined as interval between first assessment at which criteria for ≤1% BCR-ABL1IS are met until earliest date at which loss of ≤1% BCR-ABL1IS occurs, or criteria for progression accelerated phase (AP) or blast Phase (BP) of chronic myeloid leukemia (CML) are met. Loss of ≤1% BCR-ABL1IS is an increase to \>1% of BCR-ABL1IS. Progression to AP: ≥15% and \<30% blasts in peripheral blood or bone marrow or ≥20% basophils in peripheral blood or bone marrow or ≥30% blasts + promyelocytes in peripheral blood or bone marrow (but \<30% blasts) or \<100\*109 platelets per liter in peripheral blood unrelated to therapy or cytogenetic, genetic evidence of clonal evolution, and no extramedullary disease. Progression to BP: ≥30% blasts in peripheral blood or bone marrow or extramedullary disease other than hepatosplenomegaly. Kaplan-Meier method was used for analysis of percentage of participants who achieved DOR of 12 and 24 months.

Time frame:
12 and 24 months after the first dose of study treatment
Reported as:
Number · percentage of participants
Kaplan-Meier Estimate of Duration of Response (DOR) of <=1% BCR-ABL1 IS (MR2) at Months 12 and 24
percentage of participantsTreatment Period: Cohort A: Ponatinib 45 mgTreatment Period: Cohort B: Ponatinib 30 mgTreatment Period: Cohort C: Ponatinib 15 mg
Month 1279.13 (64.5 to 88.3)79.20 (61.2 to 89.5)90.10 (72.4 to 96.7)
Month 2473.89 (59.9 to 83.6)77.91 (60.6 to 88.3)88.31 (71.8 to 95.4)
SecondaryKaplan-Meier Estimate of Duration of Response (DOR) of Major Molecular Response (MMR/MR3)

Duration of MMR/MR3 is defined as interval between first assessment at which criteria for MMR are met until earliest date at which loss of MMR occurs, or criteria for progression (progression to AP or BP of CML) are met. Participants remaining in MMR will be censored at last date at which criteria for MMR are met. Loss of MMR is an increase to \>0.1% of BCR-ABL1IS. Progression to AP: \>= 15% and \<30% blasts in peripheral blood or bone marrow or \>=20% basophils in peripheral blood or bone marrow or \>=30% blasts+promyelocytes in peripheral blood or bone marrow (but \<30% blasts) or \<100\*109 platelets/L in peripheral blood unrelated to therapy or cytogenetic, genetic evidence of clonal evolution, and no extramedullary disease. Progression to BP: \>=30% blasts in peripheral blood or bone marrow or extramedullary disease other than hepatosplenomegaly. Kaplan-Meier method was used for analysis of percentage of participants who achieved DOR of 12 and 24 months.

Time frame:
12 and 24 months after the first dose of study treatment
Reported as:
Number · percentage of participants
Kaplan-Meier Estimate of Duration of Response (DOR) of Major Molecular Response (MMR/MR3)
percentage of participantsTreatment Period: Cohort A: Ponatinib 45 mgTreatment Period: Cohort B: Ponatinib 30 mgTreatment Period: Cohort C: Ponatinib 15 mg
Month 1288.97 (69.5 to 96.3)93.33 (61.3 to 99.0)94.74 (68.1 to 99.2)
Month 2482.94 (67.4 to 91.5)74.77 (52.1 to 87.8)95.45 (71.9 to 99.3)
SecondaryDuration of Response in MR2 Responders

Duration of response in "responders" was defined as any participants who achieved ≤1% BCR-ABL1IS (MR2) at any time during the study. Responders were defined as those participants who met all of the following: were randomized and treated, responded at 12 months after the initiation of study treatment, and underwent baseline polymerase chain reaction (PCR) assessment.

Time frame:
Baseline up to approximately 8.9 years
Reported as:
Median · months
Duration of Response in MR2 Responders
monthsTreatment Period: Cohort A: Ponatinib 45 mgTreatment Period: Cohort B: Ponatinib 30 mgTreatment Period: Cohort C: Ponatinib 15 mg
Duration of Response in MR2 RespondersNA (61.5 to NA)NA (NA to NA)NA (NA to NA)
SecondaryTime to Response (MR2)

Time to response was defined as the time interval from the date of the first dose of the study drug until the initial observation of CR or PR for participants with confirmed CR/PR. Response was defined as any participants who achieved ≤1% BCR-ABL1IS (MR2) at any time during the study. CR for target lesion: disappearance of all extranodal lesions and all pathological lymph nodes must have decreased to \<10 mm in short axis. CR for non-target lesion: Disappearance of all extranodal non-target lesions, all lymph nodes must be non-pathological in size (\<10mm short axis) and normalization of tumor marker level. PR: at least a 30% decrease in the SLD of target lesions, taking as reference the Baseline sum diameters.

Time frame:
Baseline up to approximately 5 years
Reported as:
Median · months
Time to Response (MR2)
monthsTreatment Period: Cohort A: Ponatinib 45 mgTreatment Period: Cohort B: Ponatinib 30 mgTreatment Period: Cohort C: Ponatinib 15 mg
Time to Response (MR2)6.00 (5.8 to 6.1)3.11 (3.0 to 6.0)6.18 (3.1 to 14.5)
SecondaryPercentage of Participants With Progression to Accelerated Phase (AP)-Chronic Myeloid Leukemia (CML) or Blast Phase (BP)-CML

Progression to AP is defined as: \>=15% and \<30% blasts in peripheral blood or bone marrow or \>=20% basophils in peripheral blood or bone marrow or \>=30% blasts + promyelocytes in peripheral blood or bone marrow (but \<30% blasts) or \<100\*109 platelets/L in peripheral blood unrelated to therapy or cytogenetic, genetic evidence of clonal evolution, and no extramedullary disease. Progression to BP is defined as: \>=30% blasts in peripheral blood or bone marrow or extramedullary disease other than hepatosplenomegaly.

Time frame:
From first dose date of study treatment up to approximately 8.9 years
Reported as:
Number · percentage of participants
Percentage of Participants With Progression to Accelerated Phase (AP)-Chronic Myeloid Leukemia (CML) or Blast Phase (BP)-CML
percentage of participantsTreatment Period: Cohort A: Ponatinib 45 mgTreatment Period: Cohort B: Ponatinib 30 mgTreatment Period: Cohort C: Ponatinib 15 mg
Progressed to AP-CML11.711.613.8
Progressed to BP-CML3.21.12.1
SecondaryProgression-free Survival (PFS)

PFS was defined as the interval between the first dose date of study treatment and the first date at which the criteria for progression were met (progression to the AP or BP of CML), or death due to any cause, censored at the last response assessment. Progression to AP was defined as: \>=15% and \<30% blasts in peripheral blood or bone marrow or \>=20% basophils in peripheral blood or bone marrow or \>=30% blasts + promyelocytes in peripheral blood or bone marrow (but \<30% blasts) or \<100\*109 platelets/L in peripheral blood unrelated to therapy or cytogenetic, genetic evidence of clonal evolution, and no extramedullary disease. Progression to BP was defined as: \>=30% blasts in peripheral blood or bone marrow or extramedullary disease other than hepatosplenomegaly.

Time frame:
Up to approximately 8.9 years
Reported as:
Median · months
Progression-free Survival (PFS)
monthsTreatment Period: Cohort A: Ponatinib 45 mgTreatment Period: Cohort B: Ponatinib 30 mgTreatment Period: Cohort C: Ponatinib 15 mg
Progression-free Survival (PFS)NA (63.5 to NA)75.04 (45.0 to NA)NA (45.8 to NA)
SecondaryOverall Survival (OS)

OS was defined as the interval between the first dose of study treatment and death due to any cause, censored at the last contact date when the participant was alive.

Time frame:
Up to approximately 8.9 years
Reported as:
Median · months
Overall Survival (OS)
monthsTreatment Period: Cohort A: Ponatinib 45 mgTreatment Period: Cohort B: Ponatinib 30 mgTreatment Period: Cohort C: Ponatinib 15 mg
Overall Survival (OS)NA (NA to NA)NA (NA to NA)NA (NA to NA)

Adverse events

Collected over From first dose up to 30 days after last dose of the study drug (up to approximately 9.8 years). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment Period: Cohort A: Ponatinib 45 mg19/94 (20.2%)38/94 (40.4%)93/94 (98.9%)
Treatment Period: Cohort B: Ponatinib 30 mg16/95 (16.8%)33/94 (35.1%)90/94 (95.7%)
Treatment Period: Cohort C: Ponatinib 15 mg14/94 (14.9%)39/94 (41.5%)90/94 (95.7%)
Close-out Period: Cohort A: Ponatinib 45 mg0/27 (0%)1/27 (3.7%)19/27 (70.4%)
Close-out Period: Cohort B: Ponatinib 30 mg0/17 (0%)3/17 (17.6%)16/17 (94.1%)
Close-out Period: Cohort C: Ponatinib 15 mg0/17 (0%)0/17 (0%)13/17 (76.5%)
Most frequent serious events
Showing 10 of 105
Most frequent serious events
EventTreatment Period: Cohort A: Ponatinib 45 mgTreatment Period: Cohort B: Ponatinib 30 mgTreatment Period: Cohort C: Ponatinib 15 mgClose-out Period: Cohort A: Ponatinib 45 mgClose-out Period: Cohort B: Ponatinib 30 mgClose-out Period: Cohort C: Ponatinib 15 mg
Cerebral ischaemiaNervous system disorders0/940/940/940/271/170/17
Renal artery stenosisRenal and urinary disorders0/940/940/940/271/170/17
Uterine polypReproductive system and breast disorders0/940/940/940/271/170/17
ThrombocytopeniaBlood and lymphatic system disorders5/942/945/940/270/170/17
PyrexiaGeneral disorders4/941/941/940/270/170/17
Adenocarcinoma gastricNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/940/940/941/270/170/17
Vertebrobasilar strokeNervous system disorders0/940/940/941/270/170/17
AnaemiaBlood and lymphatic system disorders3/940/940/940/270/170/17
Atrial fibrillationCardiac disorders2/943/941/940/270/170/17
NeutropeniaBlood and lymphatic system disorders2/941/943/940/270/170/17
Most frequent other events
Showing 10 of 96
Most frequent other events
EventTreatment Period: Cohort A: Ponatinib 45 mgTreatment Period: Cohort B: Ponatinib 30 mgTreatment Period: Cohort C: Ponatinib 15 mgClose-out Period: Cohort A: Ponatinib 45 mgClose-out Period: Cohort B: Ponatinib 30 mgClose-out Period: Cohort C: Ponatinib 15 mg
ThrombocytopeniaBlood and lymphatic system disorders40/9436/9436/944/270/170/17
HypertensionVascular disorders31/9438/9427/944/274/171/17
NeutropeniaBlood and lymphatic system disorders29/9423/9424/941/270/170/17
Alanine aminotransferase increasedInvestigations25/949/9421/942/270/173/17
Lipase increasedInvestigations24/9419/9414/940/270/170/17
ArthralgiaMusculoskeletal and connective tissue disorders12/9423/9415/940/270/170/17
AnaemiaBlood and lymphatic system disorders22/9419/9417/941/270/170/17
HeadacheNervous system disorders19/9421/9420/940/271/170/17
HypertriglyceridaemiaMetabolism and nutrition disorders15/9410/949/945/270/171/17
PyrexiaGeneral disorders17/947/9410/940/270/170/17

Baseline characteristics

Safety Population included all participants who received at least one dose of study drug.

Age, Continuous
Age, Continuous(years)Treatment Period: Cohort A: Ponatinib 45 mgTreatment Period: Cohort B: Ponatinib 30 mgTreatment Period: Cohort C: Ponatinib 15 mgTotal
Mean47.7 ± 14.7748.5 ± 12.9048.8 ± 12.7148.3 ± 13.45
Sex: Female, Male
Sex: Female, Male(Participants)Treatment Period: Cohort A: Ponatinib 45 mgTreatment Period: Cohort B: Ponatinib 30 mgTreatment Period: Cohort C: Ponatinib 15 mgTotal
Female445641141
Male503853141
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Treatment Period: Cohort A: Ponatinib 45 mgTreatment Period: Cohort B: Ponatinib 30 mgTreatment Period: Cohort C: Ponatinib 15 mgTotal
Hispanic or Latino22262068
Not Hispanic or Latino706772209
Unknown or Not Reported2125
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Treatment Period: Cohort A: Ponatinib 45 mgTreatment Period: Cohort B: Ponatinib 30 mgTreatment Period: Cohort C: Ponatinib 15 mgTotal
Race — Asian16121543
Race — Black or African American1236
Race — White737772222
Race — Unknown0134
Race — Other2103
Race — Missing2114
Region of Enrollment
Region of Enrollment(Participants)Treatment Period: Cohort A: Ponatinib 45 mgTreatment Period: Cohort B: Ponatinib 30 mgTreatment Period: Cohort C: Ponatinib 15 mgTotal
Argentina1516738
Austria0022
Chile79925
Denmark0011
France2125
United Kingdom14712
Hong Kong1326
Italy0303
Japan52411
Poland46515
Russia383138107
Singapore4329
Korea, Republic Of0325
Spain3025
Sweden0213
Taiwan, Province Of China4127
United States108725
Canada0101
Portugal0112
Weight
Weight(kg)Treatment Period: Cohort A: Ponatinib 45 mgTreatment Period: Cohort B: Ponatinib 30 mgTreatment Period: Cohort C: Ponatinib 15 mgTotal
Mean78.14 ± 20.84177.56 ± 18.37576.71 ± 17.43477.47 ± 18.879
Height
Height(meter)Treatment Period: Cohort A: Ponatinib 45 mgTreatment Period: Cohort B: Ponatinib 30 mgTreatment Period: Cohort C: Ponatinib 15 mgTotal
Mean1.68 ± 0.1041.68 ± 0.0981.68 ± 0.0901.68 ± 0.097
Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) Score
Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) Score(Participants)Treatment Period: Cohort A: Ponatinib 45 mgTreatment Period: Cohort B: Ponatinib 30 mgTreatment Period: Cohort C: Ponatinib 15 mgTotal
Score= 0747372219
Score= 119202261
Score= 21102

5 further baseline measures are reported on the registry.

08

Study locations

86 sites
  • Emory University Winship Cancer Institute
    Atlanta, Georgia 30322, United States
  • Indiana Blood & Marrow Transplantation
    Indianapolis, Indiana 46237, United States
  • University of Maryland Medical Center
    Baltimore, Maryland 21201, United States
  • Michigan Medicine
    Ann Arbor, Michigan 48109, United States
  • Barbara Ann Karmanos Cancer Institute
    Detroit, Michigan 48201, United States
  • University of Minnesota Medical School
    Minneapolis, Minnesota 55455, United States
  • University of Nebraska Medical Center
    Omaha, Nebraska 68198, United States
  • Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • Memorial Sloan-Kettering Cancer Center - New York
    New York, New York 10065, United States
  • NewYork-Presbyterian Weill Cornell Medical Center
    New York, New York 10065, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • Cleveland Clinic Taussig Cancer Institute Main Campus
    Cleveland, Ohio 44195, United States
  • Oregon Health and Science University
    Portland, Oregon 97239, United States
  • Abramson Cancer Center
    Philadelphia, Pennsylvania 19104, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • University of Utah Huntsman Cancer Institute
    Salt Lake City, Utah 84112, United States
  • Fundaleu
    Ciudad Autonoma de Buenos Aires, Buenos Aires C1114AAN, Argentina
  • Hospital General de Agudo Jose Maria Ramos Mejia
    Ciudad Autonoma de Buenos Aires, Buenos Aires C1221ADC, Argentina
  • Hospital Italiano La Plata
    La Plata, Buenos Aires B1900AXI, Argentina
  • Royal North Shore Hospital
    Saint Leonards, New South Wales 2065, Australia
  • Royal Adelaide Hospital
    Adelaide, South Australia 5000, Australia
  • Princess Margaret Hospital - Toronto
    Toronto, Ontario M5G 2M9, Canada
  • Jewish General Hospital
    Montreal, Quebec H3T 1E2, Canada
  • Saskatchewan Cancer Agency
    Regina, Saskatchewan S4T 7T1, Canada
  • Hospital del Salvador
    Providencia, Santiago Metropolitan 7500922, Chile
  • Centro de Investigaciones Clinicas Vina del Mar
    Viña del Mar, Valparaiso 2540364, Chile
  • Ustav Hematologie a Krevni Transfuze Praha
    Prague, Prague 12820, Czechia
  • Fakultni Nemocnice Olomouc
    Olomouc, 772 00, Czechia
  • Aarhus University Hospital
    Aarhus C, \Aarhus DK-8000, Denmark
  • Centre de Lutte Contre le Cancer - Institut Bergonie
    Bordeaux, Aquitaine 33076, France
  • Centre Hospitalier Regional Universitaire de Lille
    Lille, Hauts-de-France 59037, France
  • Centre Hospitalier Universitaire de Nancy Hopital de Brabois
    Vandœuvre-lès-Nancy, Lorraine 54511, France
  • Institut Universitaire du Cancer de Toulouse Oncopole
    Toulouse, Midi-pyrenees 31059, France
  • Center Hospitalier Universitaire d'Angers
    Angers, Pays de la Loire Region 49933, France
  • Centre Hospitalier Universitaire de Nantes Hotel Dieu
    Nantes, Pays de la Loire Region 44093, France
  • Centre Hospitalier Universitaire de Poitiers
    Poitiers, Poitou-charentes 86021, France
  • Centre Hospitalier Universitaire de Nice Hopital l'Archet
    Nice, Provence-Alpes-Côte d'Azur Region 06202, France
  • Universitaetsklinikum Heidelberg
    Mannheim, Baden-Wurttemberg 68169, Germany
  • Universitatsklinikum Ulm
    Ulm, Baden-Wurttemberg 89081, Germany
  • Universitatsmedizin Rostock
    Rostock, Mecklenburg-Vorpommern 18057, Germany
  • Uniklinik RWTH Aachen
    Aachen, North Rhine-Westphalia 52074, Germany
  • Universitaetsklinikum Essen
    Essen, North Rhine-Westphalia 45147, Germany
  • Universitatsklinikum Jena
    Jena, Thuringia 07747, Germany
  • Charite Universitatsmedizin Berlin
    Berlin, 13353, Germany
  • Universitatsklinikum Hamburg-Eppendorf
    Hamburg, 20246, Germany
  • Queen Mary Hospital
    Hong Kong, 852, Hong Kong
  • Azienda Ospedaliera San Gerardo di Monza
    Monza, Monza E Brianza 20090, Italy
  • Azienda Ospedaliera Ospedali Riuniti Marche Nord
    Pesaro, Pesaro E Urbino 61100, Italy
  • Azienda Ospedaliero - Universitaria Policlinico - Vittorio Emanuele
    Catania, 95124, Italy
  • Azienda Ospedaliera Universitaria San Martino
    Genova, 16132, Italy
  • Azienda Sanitaria Locale di Pescara Ospedale Civile Dello Spirito Santo
    Pescara, 65124, Italy
  • Sapienza Universita Di Roma
    Roma, 00161, Italy
  • AOUI - Ospedale Policlinico "Giambattista Rossi" di Borgo Roma
    Verona, 37134, Italy
  • Malopolskie Centrum Medyczne
    Krakow, Lesser Poland Voivodeship 30-510, Poland
  • Samodzielny Publiczny Szpital Kliniczny Nr 1 we Wroclawiu
    Wroclaw, Lower Silesian Voivodeship 50-367, Poland
  • Instytut Hematologii i Transfuzjologii
    Warsaw, Masovian Voivodeship 02-776, Poland
  • Uniwersyteckie Centrum Kliniczne
    Gdansk, Pomeranian Voivodeship 80-952, Poland
  • Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika w Lodzi
    Lodz, Łódź Voivodeship 93-510, Poland
  • Instituto Portugues de Oncologia de Lisboa Francisco Gentil
    Lisbon, 1090-023, Portugal
  • Centro Hospitalar Sao Joao
    Porto, 4200-319, Portugal
  • Rostov State Medical University
    Rostov-on-Don, Rostov Oblast 344022, Russia
  • Chelyabinsk Regional Clinical Hospital
    Chelyabinsk, 454076, Russia
  • Kemerovo Regional Clinical Hospital
    Kemerovo, 650066, Russia
  • GBUZ Moscow Clinical Scientific Center DZM
    Moscow, 111123, Russia
  • Russian Academy of Medical Science
    Moscow, 125167, Russia
  • FGU Russian Scientific Research Institute of Hematology and Transfusiology
    Saint Petersburg, 191024, Russia
  • Almazov Federal North-West Medical Research Centre of Department of Health of Russian Federation
    Saint Petersburg, 197341, Russia
  • Samara State Medical University
    Samara, 443099, Russia
  • Saratov State Medical University
    Saratov, 355018, Russia
  • Singapore General Hospital
    Singapore, 169856, Singapore
  • The Catholic University of Korea, Seoul St. Mary's Hospital
    Seoul, 6591, South Korea
  • Hospital Regional Universitario Carlos Haya
    Málaga, Andalusia 29010, Spain
  • Hospital Universitario de Gran Canaria Doctor Nergrin
    Las Palmas de Gran Canaria, LAS Palmas 35010, Spain
  • Hospital Clinic i Provincial de Barcelona
    Barcelona, 08036, Spain
  • Hospital Universitario de La Princesa
    Madrid, 28006, Spain
  • Hospital Universitario Ramon Y Cajal
    Madrid, 28034, Spain
  • Hospital Clinico Universitario de Valencia
    Valencia, 46010, Spain
  • Akademiska Sjukhuset
    Uppsala, 751 85, Sweden
  • University Hospital Zurich
    Zurich, 8091, Switzerland
  • National Taiwan University Hospital
    Taipei, 100, Taiwan
  • Royal Liverpool University Hospital NHS Trust
    Liverpool, England L7 8XP, United Kingdom
  • King's College Hospital NHS Foundation Trust
    London, England SE5 9RS, United Kingdom
  • Imperial College Healthcare NHS Trust
    London, England W12 0NN, United Kingdom
  • Nottingham City Hospital NHS Trust
    Nottingham, England NG5 1PB, United Kingdom
  • Churchill Hospital
    Oxford, England OX3 7LE, United Kingdom
  • Beatson West of Scotland Cancer Centre
    Glasgow, Scotland G12 0YN, United Kingdom
09

References and documents

Publications

  • Kantarjian HM, Jabbour E, Deininger M, Abruzzese E, Apperley J, Cortes J, Chuah C, DeAngelo DJ, DiPersio J, Hochhaus A, Lipton J, Nicolini FE, Pinilla-Ibarz J, Rea D, Rosti G, Rousselot P, Shah NP, Talpaz M, Srivastava S, Ren X, Mauro M. Ponatinib after failure of second-generation tyrosine kinase inhibitor in resistant chronic-phase chronic myeloid leukemia. Am J Hematol. 2022 Nov;97(11):1419-1426. doi: 10.1002/ajh.26686. Epub 2022 Aug 30. PubMed 36054756 ↗
  • Cortes J, Apperley J, Lomaia E, Moiraghi B, Undurraga Sutton M, Pavlovsky C, Chuah C, Sacha T, Lipton JH, Schiffer CA, McCloskey J, Hochhaus A, Rousselot P, Rosti G, de Lavallade H, Turkina A, Rojas C, Arthur CK, Maness L, Talpaz M, Mauro M, Hall T, Lu V, Srivastava S, Deininger M. Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial. Blood. 2021 Nov 25;138(21):2042-2050. doi: 10.1182/blood.2021012082. PubMed 34407543 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2015 to primary completion in Apr 2020, 57 months.

Results were first posted in Jun 2021, 1 year 1 month after primary completion.

Of 49 phase 2 interventional studies under Leukemia, Myeloid, Chronic-Phase, half reached primary completion within 70 months of starting (the median), counting those still running; a quarter within 43 and three quarters within 132. This study's 57 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 2, 2015
First posted
Jun 10, 2015
StartActual
Jul 13, 2015
Primary completionActual
Apr 29, 2020
CompletionActual
Apr 23, 2025
Results first posted
Jun 14, 2021
Last update
Mar 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02467270
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Jun 10, 2015
Start date
Jul 13, 2015
Primary completion
Apr 29, 2020
Completion
Apr 23, 2025
Results posted
Jun 14, 2021
Last update
Mar 17, 2026

Study contacts

Medical Director
study director · Takeda

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ponatinib

Start the discussion